Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma

Thursday, June 2, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

Clinical Study Seeks to Evaluate MORAb-004 as a Single Agent for Extending Progression-Free Survival of Patients with Metastatic Disease

Contacts:  

Media Inquiries

Investor Inquiries

Terry Cushmore

Rod Dausch

Morphotek, Inc.

Morphotek, Inc.

610-423-6197

610-423-6111

[email protected]

[email protected]

Media Inquiries

Investor Inquiries

Lynn Kenney

Alex Scott

Eisai Inc.

Eisai Inc.

201-746-2294

201-746-2177

[email protected]

[email protected]



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store